Rucaparib Extends PFS in Deleterious BRACA1/2-Mutated Relapsed Ovarian Cancer

Amit M. Oza, MD, discusses progression-free survival findings from the phase 3 ARIEL4 clinical trial.

Amit M. Oza, MD, a senior scientist in the Princess Margaret Cancer Centre Cancer Clinical Research Unit at Princess Margaret Cancer Centre and co-leader of the Ovarian Cancer Translational Research Initiative at the Ontario Institute for Cancer Research, discusses progression-free survival (PFS) findings from the phase 3 ARIEL4 clinical trial (NCT02855944).

Results from the study published in the Lancet Oncology indicate that rucaparib prolong PFS compared with platinum-based chemotherapy.

Transcription:

0:08 | The previous studies have been looking at early phase studies followed by randomized studies that have looked at its role in the maintenance setting. In ARIEL4, we were looking at patients with a deleterious BRCA1/BRCA2 mutation, and then really looking at the role of single-agent rucaparib in treating recurrent disease. And there were 3 different types of patients that were identified. These included patients that are fully platinum sensitive, patients who are in partially platinum sensitive, and then patients who are deemed to be platinum resistant.

1:02 | In this study, rucaparib was compared head-to-head with platinum-based chemotherapy in platinum sensitive patients. The progression-free survival results were presented about 18 months to 2 years ago, which really showed that there was an improvement in progression-free survival that was seen in the intent-to-treat population as well as the subgroups.